Evidence map›Paper›PMID 34695230›Full record

ArticleEuropean journal of clinical investigation2022

Changes of lipoprotein(a) levels with endogenous steroid hormones.

Elena Tessitore, Kevin Dobretz, Nasser Abdalla Dhayat, Ilse Kern, Belen Ponte, Menno Pruijm, Daniel Ackermann, Sandrine Estoppey, Michel Burnier, Pierre-Yves Martin and 5 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Changes of lipoprotein(a) levels with endogenous steroid hormones.European journal of clinical investigation · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Elena TessitoreCardiology, Geneva University Hospitals, Geneva, Switzerland.ORCID https://orcid.org/0000-0003-1680-0152
Kevin DobretzCardiology, Geneva University Hospitals, Geneva, Switzerland.
Nasser Abdalla DhayatDepartment of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Ilse KernLaboratory Medicine, Geneva University Hospitals, Geneva, Switzerland.
Belen PonteNephrology and Hypertension, Geneva University Hospitals, Geneva, Switzerland.
Menno PruijmNephrology, University Hospital Centre Vaudois (CHUV), Lausanne, Switzerland.
Daniel AckermannDepartment of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Sandrine EstoppeyCenter for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Michel BurnierNephrology, University Hospital Centre Vaudois (CHUV), Lausanne, Switzerland.
Pierre-Yves MartinNephrology and Hypertension, Geneva University Hospitals, Geneva, Switzerland.
Bruno VogtDepartment of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Nicolas VuilleumierLaboratory Medicine, Geneva University Hospitals, Geneva, Switzerland.
Murielle BochudCenter for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
François MachCardiology, Geneva University Hospitals, Geneva, Switzerland.
Georg EhretCardiology, Geneva University Hospitals, Geneva, Switzerland.
University Hospital of Geneva · CHUniversity of Bern · CHCentre universitaire de médecine générale et santé publique, Lausanne · CHUniversity Hospital of Lausanne · CH

Funding

Swiss Heart Foundation project N. FF17022Swiss National Science Foundation FN 33CM30-124087/ 140331
6 · The paper itself

Abstract

backgroundLipoprotein(a) [Lp(a)] is an LDL-like molecule that is likely causal for cardiovascular events and Lp(a) variability has been shown to be mostly of genetic origin. Exogenous hormones (hormone replacement therapy) seem to influence Lp(a) levels, but the impact of endogenous hormone levels on Lp(a) is still unknown. The aim of the study was to assess the effect of endogenous steroid hormone metabolites on Lp(a).

methodsLipoprotein(a) levels were measured in 1,021 participants from the Swiss Kidney Project on Genes in Hypertension, a family-based, multicentre, population-based prospective cohort study. Endogenous levels of 28 steroid hormone precursors were measured in 24-h urine collections from 883 individuals. Of the participants with Lp(a) data, 1,011 participants had also genotypes available.

resultsThe participants had an average age of 51 years and 53% were female. Median Lp(a) levels were 62 mg/L, and the 90

conclusionsIn this contemporary population-based study, the prevalence of a Lp(a) elevation ≥700 mg/L was 3.2%. The effect of endogenous steroid hormone levels of Lp(a) variability was small at best, suggesting a negligible impact on the wide range of Lp(a) variability.

Indexed as

AdultAgedCohort StudiesFemaleHormonesHumansLipoprotein(a)MaleMiddle AgedProspective StudiesHormonesLipoprotein(a)cardiovascular riskendogenous hormoneslipoprotein (a)

Identifiers

PMID34695230
PMCPMC9286445
OpenAlexW3211007510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.